Axsome Therapeutics Initiates ENGAGE Phase 3 Trial of Solriamfetol for the Treatment of Binge Eating DisorderGlobeNewsWire • 04/01/24
Axsome Therapeutics Announces Results of CRESCENDO Narcolepsy Patient Survey Demonstrating Unmet Needs in Treated Narcolepsy Type 1 PatientsGlobeNewsWire • 03/25/24
Axsome Therapeutics Announces AXS-12 Achieves Primary Endpoint in the SYMPHONY Phase 3 Trial in NarcolepsyGlobeNewsWire • 03/25/24
Axsome Therapeutics Initiates PARADIGM Phase 3 Trial of Solriamfetol for the Treatment of Major Depressive DisorderGlobeNewsWire • 03/19/24
Axsome Therapeutics to Present at the Leerink Partners Global Biopharma ConferenceGlobeNewsWire • 03/05/24
Axsome Therapeutics to Present at the TD Cowen 44th Annual Healthcare ConferenceGlobeNewsWire • 02/27/24
Axsome Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business UpdateGlobeNewsWire • 02/20/24
Axsome Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results on February 20GlobeNewsWire • 01/23/24
Axsome (AXSM) Surges 7.8%: Is This an Indication of Further Gains?Zacks Investment Research • 01/05/24
Axsome Therapeutics Provides Preliminary Fourth Quarter and Full Year 2023 Net Revenue and 2024 Anticipated MilestonesGlobeNewsWire • 01/04/24